RPRenuka Pangaluri

Renuka Pangaluri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Renuka Pangaluri has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Utility of preoperative growth differentiation factor-15 as a prognostic marker for ICU stay in patients undergoing coronary artery bypass grafting (CABG)

    by Shalini Mettupalayam Sridhar, Renuka Pangaluri, Vinodhini Vellore Mohan, Hariharan Antony Simon, Nembian Raja Rajan Bojarajan, Akshita Boominathan


  • Laboratory Detection of Pseudohyperkalaemia in a Trauma Patient: A Case Report

    by Sudharshan, P Renuka, A Raja Mydeen, Kothai Gnanamoorthy, Vm Vinodhini

    Pseudohyperkalaemia refers to a spuriously elevated serum potassium concentration resulting from laboratory artefacts and frequently poses a diagnostic and therapeutic challenge in routine clinical practice. Its significance is heightened in acute care settings, where timely and appropriate clinical decisions are critical. The present report describes the case of a 53-year-old male who developed pseudohyperkalaemia following polytrauma with extensive lower limb injuries, including a crush injury to the left foot. Initial potassium levels were within the normal range; however, subsequent elevations were observed in the absence of Electrocardiographic (ECG) changes or clinical features suggestive of true hyperkalaemia. Further evaluation revealed thrombocytosis, a recognised cause of pseudohyperkalaemia due to potassium release from activated platelets during clot formation. The present case is notable because the diagnostic dilemma occurred in a critically injured trauma patient, where differentiating true hyperkalaemia from pseudohyperkalaemia had significant therapeutic implications. Prompt recognition prevented unnecessary administration of potassium-lowering therapy, which could have resulted in iatrogenic hypokalaemia. Correlation of laboratory findings with clinical assessment, along with the use of plasma rather than serum samples, aided in confirming the diagnosis. The present report highlights the importance of maintaining a high index of suspicion for pseudohyperkalaemia in patients with thrombocytosis or leukocytosis, particularly in trauma and critical care settings. Awareness of this phenomenon can prevent mismanagement, enhance patient safety, and guide rational treatment decisions.

  • Open Access

    Association between fetuin-a levels and diabetic nephropathy in patients with type 2 diabetes mellitus

    by Anns George, Gayathri B, Vinodhini V.M, Renuka P, Meenakshi Sundari S. N

    Background: Fetuin-A is a liver secreted glycoprotein that plays a pivotal role in various physiological processes including insulin resistance, inflammation, and inhibition of ectopic calcification. This study aimed to estimate and compare the level of serum fetuin-A in T2DM patients with and without nephropathy. Material and Methods: This cross-sectional study was conducted with 84 participants, divided into three groups. Group I includes (n = 28) healthy individuals without any history of T2DM or DN, Group II includes (n = 28) T2DM patients without nephropathy, and Group III includes (n = 28) T2DM patients with nephropathy. The biochemical parameters such as fasting and postprandial plasma glucose, HbA1c, Renal function tests, lipid profiles and fetuin-A were analysed, and the estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio (ACR) were calculated. Results: Fetuin-A levels were significantly lower in diabetic nephropathy (DN) patients compared to both healthy controls and Type 2 Diabetes Mellitus (T2DM) patients without nephropathy (p < 0.05). There is a significant difference in Fetuin-A levels between healthy controls and T2DM patients with nephropathy. Fetuin-A was negatively correlated with ACR . ROC analysis revealed a sensitivity of 67.9% and a specificity of 64.3% for fetuin-A. Conclusion: The study suggests that serum Fetuin-A levels are significantly reduced in individuals with diabetic nephropathy and serve as a potential biomarker for the early detection and monitoring for Diabetic nephropathy.

  • Association of Serum TREM2 with Acute Coronary Syndrome and its Severity: A Cross-sectional Study

    by Sudharhsan, P Renuka, Vm Vinodhini, M Vengatesh, Ka Arul Senghor

    Introduction: Acute Coronary Syndrome (ACS) remains a major cause of morbidity and mortality worldwide, primarily driven by plaque rupture and thrombotic occlusion in coronary arteries. Traditional biomarkers provide limited insight into the inflammatory and lipid-driven mechanisms underlying plaque instability. Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2), a shed form of a membrane-bound receptor expressed on macrophages and other myeloid cells, has been implicated in lipid metabolism, immune regulation and tissue homeostasis. Although its role in neurodegenerative and metabolic disorders has been increasingly recognised, its relevance in atherosclerosis and acute coronary events is still being elucidated. Exploring sTREM2 in this setting may offer novel perspectives on immune-metabolic activity in coronary artery disease. Aim: To investigate the association between serum sTREM2 levels and ACS, as well as disease severity. Materials and Methods: The present observational crosssectional study was conducted at the Department of Biochemistry, SRM Medical College Hospital and Research Centre, Potheri, SRM Nagar, Kattankulathur, Tamil Nadu, India, between December 2023 and August 2024. A total of 180 participants were enrolled, including 90 newly diagnosed ACS patients and 90 age- and gender-matched healthy controls. Inclusion criteria for the ACS group included adults aged over 25 years with a confirmed diagnosis of ACS {STElevation Myocardial Infarction (STEMI), Non ST-Elevation Myocardial Infarction (NSTEMI), or unstable angina} based on clinical presentation, Electrocardiographic (ECG) changes and cardiac biomarkers. Controls were healthy volunteers with no history of cardiovascular disease. Serum sTREM2 levels, lipid profile, Apolipoprotein B (ApoB) and high-sensitivity C-Reactive Protein (hs-CRP) were measured. ACS severity was assessed using the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX I) score. Demographic parameters including age, gender, Body Mass Index (BMI). Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 22.0. Data normality was assessed using the Shapiro-Wilk test. Group comparisons were conducted using the Mann-Whitney U test and Kruskal-Wallis test. Spearman’s correlation was used to evaluate relationships between variables and Receiver Operating Characteristic (ROC) curve analysis assessed the diagnostic utility of biomarkers. A p-value <0.05 was considered statistically significant. Results: Serum sTREM2 levels were significantly higher in ACS patients {115.19 (78.18-191.67) pg/mL} compared to controls {70.74 (51.16-89.03) pg/mL} (p<0.001). ACS patients also exhibited elevated hs-CRP, ApoB, Total Cholesterol (TC), LowDensity Lipoprotein (LDL) and Very Low-Density Lipoprotein (VLDL), along with reduced High-Density Lipoprotein (HDL) levels. A positive correlation was identified between sTREM2 and body weight, BMI, TC, LDL and the TC/HDL ratio, while a negative correlation was noted with HDL. sTREM2 levels increased progressively with ACS severity as determined by the SYNTAX I score. No significant correlation was found between sTREM2 and hs-CRP or ApoB. ROC analysis demonstrated moderate diagnostic accuracy for sTREM2, with an Area Under the Curve (AUC) of 0.771. Conclusion: The present study demonstrates that serum sTREM2 levels are significantly elevated in ACS patients and correlate with disease severity. These findings suggest that sTREM2 may serve as a novel biomarker for ACS stratification, providing insights into the inflammatory and lipid-related mechanisms driving disease progression. Further longitudinal studies are required to validate its prognostic and clinical utility.

  • Open Access

    Paraprotein interference in bilirubin assays: A case of multiple myeloma highlighting the reliability of dry chemistry

    by Aditya Narayanan S, Ramya Devi D A, Renuka Pangaluri, Vinodhini V M, Arul Senghor K A

    The presence of paraproteins in multiple myeloma can cause analytical interference, resulting in unusual and misleading biochemical outcomes. An uncommon but clinically relevant finding is the reporting of a negative direct bilirubin result on wet chemistry analyzers—an impossible outcome that strongly suggests analytical interference. A 60-year-old male presented with nonspecific symptoms. Liver function tests carried out on a wet chemistry analyzer indicated a total bilirubin of 0.39 mg/dL and a direct bilirubin of −7.67 mg/dL, which was not physiologically possible. There was no evidence of jaundice, and imaging appeared normal. Repeat testing with a dry chemistry analyzer indicated a total bilirubin of 1.0 mg/dL and a direct bilirubin of 0.1 mg/dL, aligning with the clinical picture. Further investigations confirmed the diagnosis of multiple myeloma with IgG-kappa monoclonal gammopathy. The discrepancy was attributed to paraprotein interference in the wet chemistry method. This case highlights a rare but important laboratory artifact—negative direct bilirubin due to paraprotein interference—and emphasizes the reliability of dry chemistry in such scenarios. Awareness of this interference is important for accurate diagnosis and avoiding unnecessary workup.

  • Association of Cardiometabolic Risk and Sleep Quality among Adults with Self-reported Sleep Disordered Breathing: A Cross-sectional Study

    by Elumalai Praveen, Manisanthakumari Sudharshan, P Renuka, B Gayathri, Vm Vinodhini, Elumalai Yashwantha, Vijukumar Lakshmi, N Prasath

    Introduction: Sleep Disordered Breathing (SDB) refers to the periodic disruption of breathing that occurs during sleep. As a result, the affected individuals experience poor sleep quality. The effects of the same include daytime fatigue, sleepiness, functional impairment, and an overall reduction in quality of life. Recently, several studies have linked SDB with obesity, diabetes, and Cardiovascular Disease (CVD). Aim: The aim of this study was to compare the cardiometabolic risk and its correlation with sleep quality among individuals with and without self-reported SDB aged between 30-50 years. Materials and Methods: The present analytical cross-sectional study was conducted at SRM Medical College, Hospital and Research Centre, Chengalpattu, Tamil Nadu, India, from January 2024 - April 2024. The study involved 136 participants irrespective of gender, aged between 30-50 years. Out of 136 participants, 68 were apparently healthy individuals without SDB, and the remaining 68 were individuals with self-reported SDB based on the Neck Circumference (NC), Obesity, Snoring, Age, and Sex (NoSAS) score. A score of ≥8 was considered SDB positive, and sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. Anthropometric measurements such as Weight (kg), Height (cm), Waist Circumference (WC) (cm), Neck Circumference (NC) (cm) and Body Mass Index (BMI) (Kg/m2 ) were noted. Biochemical parameters such as Fasting plasma glucose (FPG) and lipid profile [Total Cholesterol (TC), Triglycerides (TGL), Low-density Lipoprotein cholesterol (LDL-C), High-density Lipoprotein cholesterol (HDL-C)] were also analysed. Descriptive statistics, student’s t test, MannWhitney U test, Spearman correlation test, Chi-square test were used to statistically analyse the data. Results: In the present study, the average age of SDB positive group was 40.88±6.04 years and SDB negative group was 41.20±5.6 years. The SDB positive group had a male to female ratio of 40:28 and the SDB negative group had a male to female ratio of 23:45. Furthermore, the SDB positive group had higher BMI, NC, WC, biochemical parameters (FPG, TC, TGL, LDL-C) as well as lower HDL-C levels and poor sleep quality, compared to the SDB negative group. Conclusion: Individuals with SDB had poorer sleep quality and a higher risk of developing CVD as exhibited by the elevated lipid parameters, compared with that of the SDB negative group. Future studies could focus on exploring the directionality and causality of the said associations.

  • Comparison of WNT1-Inducible Signaling Pathway Protein 1 Levels in Gestational Diabetes Mellitus and Normoglycaemic Pregnancy: A Cross-sectional Study

    by D Kaviya, P Renuka, Vm Vinodhini, M Anuradha, Ak Roopa

    Introduction: Gestational Diabetes Mellitus (GDM) is a common condition that occurs in pregnancy with adverse outcomes. The Wingless and Int-1 ( WNT) signaling pathway is related to adipogenesis as well as inflammatory processes during pregnancy. WNT Inducible Signaling Pathway Protein 1 (WISP-1) has recently been described as a novel adipokine, which may participate in impaired glucose homeostasis. WISP-1 plays a critical part in the pathogenesis of obesity- and inflammationrelated diseases. Aim: To estimate WISP 1 levels and their association with hepatic steatosis and insulin resistance in GDM. Materials and Methods: The present cross-sectional study was conducted in the Obstetrics Antenatal Outpatient Department (OPD) of SRM Medical College Hospital and Research Centre, Kattankulathur, Chengalpattu District, Tamil Nadu, India, from December 2023 to May 2024. A total of 41 GDM patients and 41 normal healthy pregnant women between 12 to 28 weeks of pregnancy were included. Pregnant women were diagnosed as GDM, based on the Diabetes in Pregnancy Study Group India criteria (DIPSI). The biochemical analytes such as fasting plasma glucose, Glucose Challenge Test (GCT), Total Cholesterol (TC), Triglycerides (TGL), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Aspartate Transaminase (AST), Alanine Transaminase (ALT), Hepatic Steatosis Index (HSI), WISP-1 and C-peptide levels were analysed. C-peptide derived C-Peptide Immunoreactivity Insulin Resistance (CPRIR) index, C-peptide based Homeostatic Model Assessment of Insulin Resistance (HOMA-IR CP) was calculated. Independent t-test was used for normal distribution and data was presented as mean±SD or the Mann-Whitney U test for skewed data and data presented as median (interquartile range). Correlation analysis was performed using Spearman’s correlation between parameters in GDM group. Statistical significance was defined as probability value, p<0.05. Results: The mean age was 27.17 years in GDM group while in the control group it was 25.58 years. WISP 1 levels were found to be increased in GDM patients, 114.54 (69.29, 174.7) compared to healthy pregnant women, 95.5 (67.39, 160.76), but this difference was not statistically significant (p=0.366). C peptide 0.46 (0.27, 0.88), HOMA-IR CP 1.51 (1.51, 1.53) were found to be significantly increased in GDM patients. WISP-1 does not correlate with hepatic steatosis (ρ=-0.207, p=0.193) and insulin resistance based on C peptide (ρ=-0.219, p=0.170) in GDM patients. Conclusion: WISP-1 has no correlation with hepatic steatosis and insulin resistance based on C peptide in GDM patients.


  • Comparison of WNT1-Inducible Signaling Pathway Protein 1 Levels in Gestational Diabetes Mellitus and Normoglycaemic Pregnancy: A Cross-sectional Study

    by D Kaviya, P Renuka, Vm Vinodhini, M Anuradha, Ak Roopa

    Introduction: Gestational Diabetes Mellitus (GDM) is a common condition that occurs in pregnancy with adverse outcomes. The Wingless and Int-1 ( WNT) signaling pathway is related to adipogenesis as well as inflammatory processes during pregnancy. WNT Inducible Signaling Pathway Protein 1 (WISP-1) has recently been described as a novel adipokine, which may participate in impaired glucose homeostasis. WISP-1 plays a critical part in the pathogenesis of obesity- and inflammationrelated diseases. Aim: To estimate WISP 1 levels and their association with hepatic steatosis and insulin resistance in GDM. Materials and Methods: The present cross-sectional study was conducted in the Obstetrics Antenatal Outpatient Department (OPD) of SRM Medical College Hospital and Research Centre, Kattankulathur, Chengalpattu District, Tamil Nadu, India, from December 2023 to May 2024. A total of 41 GDM patients and 41 normal healthy pregnant women between 12 to 28 weeks of pregnancy were included. Pregnant women were diagnosed as GDM, based on the Diabetes in Pregnancy Study Group India criteria (DIPSI). The biochemical analytes such as fasting plasma glucose, Glucose Challenge Test (GCT), Total Cholesterol (TC), Triglycerides (TGL), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Aspartate Transaminase (AST), Alanine Transaminase (ALT), Hepatic Steatosis Index (HSI), WISP-1 and C-peptide levels were analysed. C-peptide derived C-Peptide Immunoreactivity Insulin Resistance (CPRIR) index, C-peptide based Homeostatic Model Assessment of Insulin Resistance (HOMA-IR CP) was calculated. Independent t-test was used for normal distribution and data was presented as mean±SD or the Mann-Whitney U test for skewed data and data presented as median (interquartile range). Correlation analysis was performed using Spearman’s correlation between parameters in GDM group. Statistical significance was defined as probability value, p<0.05. Results: The mean age was 27.17 years in GDM group while in the control group it was 25.58 years. WISP 1 levels were found to be increased in GDM patients, 114.54 (69.29, 174.7) compared to healthy pregnant women, 95.5 (67.39, 160.76), but this difference was not statistically significant (p=0.366). C peptide 0.46 (0.27, 0.88), HOMA-IR CP 1.51 (1.51, 1.53) were found to be significantly increased in GDM patients. WISP-1 does not correlate with hepatic steatosis (ρ=-0.207, p=0.193) and insulin resistance based on C peptide (ρ=-0.219, p=0.170) in GDM patients. Conclusion: WISP-1 has no correlation with hepatic steatosis and insulin resistance based on C peptide in GDM patients.